United States 
Canada
EU
UKRELYVRIO/ALBRIOZA will no longer be available for new patients as of April 4, 2024. Patients on therapy as of April 4 in the U.S. and Canada who, in consultation with their physician, wish to continue can be transitioned to a free drug program.
More moments
like this
In memory of Mick, a husband and father, who was a gifted tattoo artist and musician.
Everything we do at Amylyx is centered around those living with neurodegenerative diseases. We are on a mission to discover and develop treatments for relentless neurodegenerative diseases and to help support and create more moments for the neurodegenerative disease community.
In memory of Mick, a husband and father, who was a gifted tattoo artist and musician.
And this
Kristina, living with ALS
Kristina, living with ALS
And this
In memory of Eric, a husband and father, who was a courageous skydiver and Army veteran.
Because these are the moments that truly matter.
In memory of Eric, a husband and father, who was a courageous skydiver and Army veteran.
Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy
Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS
The PHOENIX study of AMX0035 (sodium phenylbutyrate and taurursodiol [also known as ursodoxicoltaurine]; RELYVRIO® in the U.S., ALBRIOZA™ in Canada) did not meet its prespecified primary or secondary endpoints.
Patient Support Information
If you are currently on RELYVRIO, please contact the Amylyx Care Team.
In pursuit of more
Our ongoing commitment to discovery carries with it a responsibility to be transparent, set realistic expectations, and work together to make an impact. Learn more about our unique culture, approach to clinical trials and more.
Our ongoing commitment to discovery carries with it a responsibility to be transparent, set realistic expectations, and work together to make an impact. Learn more about our unique culture, approach to clinical trials and more.
Driven by People
“« When you're diagnosed with ALS [amyotrophic lateral sclerosis], you're no longer on the human clock, you're on the ALS clock. Every passing day is a lifetime to an ALS patient, and ALS patients don't have time to wait.” »
Cali, ALS caregiver
“« I feel like Amylyx is a very different company than most that I work with and truly seems like a company that cares, with a big heart, but further than that is they have a fierceness in them and they’re not going to back down from so many of the obstacles that people living with ALS have been facing.” »
Sandy, Person with ALS
“« You require help, that in the years prior, you never needed — where people have to change their lifestyle, to make your lifestyle. So, it doesn't just affect you, it affects the ones around you.” »
Greg, Person living with ALS
In the Moment
Latest News
Next
An error has occurred. Please refresh the page and retry.
Keep in touch
To stay up to date on Amylyx news, click subscribe.